Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VRAX

+ Watchlist+ Portfolio

Virax Biolabs Group Limited

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.45
52-Week Range
$0.40 – $21.75
Market Cap
$578.34K
P/E (TTM)
—
EPS (TTM)
-12.64
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.03
PEG Ratio
—
Return on Equity
-78.65%
Return on Assets
-54.23%
Gross Margin
61.90%
Operating Margin
-51515.17%
Profit Margin
0.00%
Current Ratio
9.97
Debt/Equity
0.06
Total Debt
$414.39K
Free Cash Flow
$-3.48M
Revenue Growth
684.90%
Earnings Growth
—
Enterprise Value
$-6.10M

Market Snapshot

About

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, diagnosis, and risk management of viral diseases. The company develops innovative T-Cell Test technology to assess functional immunity and immunodiagnostic products. Virax aims to advance viral disease diagnostics and prevention strategies globally.